## ALGN: Align Technology, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.95 indicates fundamental undervaluation. Caution: declining volume (40% of avg), momentum weakening (-1.9% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($150.11)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $170 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Equal-Weight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.6% (+0.7%)
- Blackrock Inc.: 6.9% (-3.4%)
- Ninety One UK Ltd: 6.3% (+136.6%)
- Capital Internationa: 4.2% (+88.6%)
- State Street Corpora: 4.0% (-1.3%)

### Key Risks

1. High beta (1.86) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Momentum deterioration: MRS_20 falling (-1.9% 5d) with bearish MACD, trend may be turning.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.95 indicates undervaluation relative to growth. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.5B |
| Beta | 1.86 |
| 52W Range | $122.00 - $237.23 |
| Short Interest | 5.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.95 |
| Forward P/E | 14.5 |
| Current P/E | 15.5 |
| YoY Growth | 7.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.1% to -0.8% (-1.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.8pp (needs >4.0% for momentum thesis). Below SMA200 (0.99x), long-term trend not supportive. MACD histogram bearish (-1.14), momentum weakening. RSI neutral at 58. Volume at 40% of 20MA suggests lack of conviction. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.77% (CS: 42) | Neutral |
| RSI_14 | 58.4 | Neutral |
| MACD Histogram | -1.14 | Bearish |
| vs SMA20 | 1.002x | Above |
| vs SMA50 | 1.089x | Above |
| vs SMA200 | 0.995x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $158.37
- **Stop Loss:** $150.11 (5.2% risk)
- **Target:** $174.89 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 159
- **Position Value:** $25,180.83
- **Portfolio %:** 25.18%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-04 (Est: $2.96)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.41 | $2.61 | +8.4% |
| 2025Q2 | $2.57 | $2.49 | -3.3% |
| 2025Q1 | $1.99 | $2.13 | +7.1% |
| 2024Q4 | $2.45 | $2.44 | -0.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*